Consumer Staples Sector Outperforms, ETF (XLP) Climbs 1.25%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Johnson & Johnson's (JNJ) Potential to Change Multiple Myeloma Treatment Paradigm in Underappreciated, Stock Remains Top Pick - Cantor Fitzgerald
January 24, 2022 6:24 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $215.00 price target on Johnson & Johnson (NYSE: JNJ) in light of the upcoming PDUFA for the company's CAR-T therapy.
The analyst quotes: "The PDUFA date for Johnson and Johnson (JNJ) and Legend Biotech's BCMA (B-cell... More
